RESUMO
Self-assembled highly uniform microspheres from star-shaped biocompatible polymers have been prepared as a local delivery system for co-loading different immunoagents together and ensuring their release in different stages, so as to realize effective cooperative immunotherapy and minimize systemic side effects.
Assuntos
Antineoplásicos/uso terapêutico , Portadores de Fármacos/química , Melanoma/tratamento farmacológico , Melanoma/terapia , Microesferas , Animais , Anticorpos/imunologia , Anticorpos/uso terapêutico , Linhagem Celular Tumoral , Sinergismo Farmacológico , Inibidores Enzimáticos/uso terapêutico , Feminino , Imunoterapia , Indolamina-Pirrol 2,3,-Dioxigenase/antagonistas & inibidores , Camundongos Endogâmicos C57BL , Polietilenoglicóis/química , Receptor de Morte Celular Programada 1/imunologia , Triptofano/análogos & derivados , Triptofano/uso terapêuticoRESUMO
A highly sensitive and selective miRNA detection approach based on a small circular probe and dual signal amplification has been reported. We successfully applied the assay for quantitative let-7a detection in cell lysates and the results agreed well with those of qRT-PCR.
Assuntos
Técnicas Biossensoriais , Corantes Fluorescentes/química , MicroRNAs/análise , DNA Catalítico/química , DNA Catalítico/metabolismo , MicroRNAs/genética , Polímeros/química , Polímeros/metabolismoRESUMO
Mesenchymal stem cells are immunoregulation cells. IL-22 plays an important role in the pathogenesis of immune thrombocytopenia. However, the effects of mesenchymal stem cells on IL-22 production in patients with immune thrombocytopenia remain unclear. Flow cytometry analyzed immunophenotypes of mesenchymal stem cells; differentiation of mesenchymal stem cells was observed by oil red O and Alizarin red S staining; cell proliferation suppression was measured with MTS; IL-22 levels of cell-free supernatants were determined by ELISA. Mesenchymal stem cells inhibited the proliferation of activated CD4(+)T cells; moreover, mesenchymal stem cells immunosuppressed IL-22 by soluble cellular factors but not PGE2. These results suggest that mesenchymal stem cells may be a therapeutic strategy for patients with immune thrombocytopenia.